Abstract
The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Current Pharmaceutical Biotechnology
Title:Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Volume: 17 Issue: 8
Author(s): Neha N. Parayath, Hayley Nehoff, Sebastien Taurin and Khaled Greish
Affiliation:
Keywords: Caco-2, Intestinal epithelium models, M cells, nanocarriers, oral delivery, oral insulin, oral vaccine, targeted delivery, transcytosis.
Abstract: The oral route is the preferred mode of administration, however the poor intestinal absorption of many bioactive compounds limit their efficacy. Several strategies have been developed to overcome the low oral bioavailability of bioactive compounds. Nanocarriers present a unique opportunity to overcome this limitation due to their diverse bioactive carriage potential, surface functionality and design flexibility. Despite these favorable characteristics, the oral delivery of nanocarriers faces several challenges which are discussed in this review. The review addresses the different mechanisms of transport across the intestinal epithelium. In addition, we will comment on the various methods and models for evaluating the intestinal permeability, with a critical discussion of the uniformity of these models in investigating the oral bioavailability of nanocarrier systems. Finally, we will discuss some of the recently developed nanocarriers for oral delivery of bioactives that show promising results.
Export Options
About this article
Cite this article as:
N. Parayath Neha, Nehoff Hayley, Taurin Sebastien and Greish Khaled, Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/1389201017666160401145608
DOI https://dx.doi.org/10.2174/1389201017666160401145608 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway
Anti-Cancer Agents in Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Predicating Candidate Cancer-Associated Genes in the Human Signaling Network Using Centrality
Current Bioinformatics Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Identification of Novel 5,6-Dimethoxyindan-1-one Derivatives as Antiviral Agents
Medicinal Chemistry DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Graphical Abstracts
Letters in Drug Design & Discovery Imaging Studies in Hypercalcemia
Current Medicinal Chemistry JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The α and β Classes Carbonic Anhydrases from Helicobacter pylori as Novel Drug Targets
Current Pharmaceutical Design The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Protein & Peptide Letters